Cargando…
Multidrug resistant Gram-negative bacilli infection in critically ill patients with Coronavirus disease 2019
PURPOSE: Rapid spread of multidrug resistant Gram-negative bacilli (MDR-GNB) infection in Coronavirus disease (COVID-19) critically ill patients was observed even in those without underlying diseases and in all age groups. We conducted a prospective cohort study to assess the risk factors for acquis...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884770/ http://dx.doi.org/10.1016/j.ijid.2021.12.130 |
_version_ | 1784660237322551296 |
---|---|
author | Allende, N. García Álvarez, V. Quiroga, M.P. Massó, M. Centrón, D. Campos, J. Fox, B. Canigia, L.B. Fernandez |
author_facet | Allende, N. García Álvarez, V. Quiroga, M.P. Massó, M. Centrón, D. Campos, J. Fox, B. Canigia, L.B. Fernandez |
author_sort | Allende, N. García |
collection | PubMed |
description | PURPOSE: Rapid spread of multidrug resistant Gram-negative bacilli (MDR-GNB) infection in Coronavirus disease (COVID-19) critically ill patients was observed even in those without underlying diseases and in all age groups. We conducted a prospective cohort study to assess the risk factors for acquisition of MDR-GNB infection in COVID-19 patients and its impact on patients´ outcome. METHODS & MATERIALS: We included 43 consecutive patients with COVID-19 from a total of 8874 patients with COVID-19 admitted into the ICU of Aleman Hospital, Argentina, from May 1st 2020 to June 30th 2021. Followed up until death or 30 days after hospital discharge. We divided them into 4 groups: colonized with MDR-GNB (G1), colonized with MDR-GNB and infected with non-carbapenem resistant bacteria (G2), colonized and infected with MDR-GNB (G3), and infected with MDR-GNB without previous colonization (G4). Microbiological sampling was performed according to patient's conditions or epidemiological surveillance. Outcomes considered were length of hospital stay (LOS), mortality and readmission rate. RESULTS: Seven, five, six and twenty five patients were distributed respectively in G1, G2, G3 and G4. Male/female ratio was 2:1 with a median age of 68 years (IQR 62–75). Chronic pulmonary disease (18.6%) was the main comorbidity. Mean LOS was 40.16 days (P=0.79). Prolonged biomedical devices used were observed in 93% of patients (P=0.33). Ventilator associated pneumonia (n:15/36) and catheter-related bloodstream infection (n:16/36) were the most frequent infections (P=0.29, P=0.69). The most common carbapenem-resistant pathogens were Klebsiella pneumoniae (n: 38/60) and Pseudomonas aeruginosa (n:8/60). All patients were exposed to antibiotics before MDR-GNB was diagnosed. The first isolation of MDR-GNB was on average 14 days after hospital admission (P=0,84). Time between MDR-GNB colonization and infection was twice as much between G2 and G3 (8.4 Vs. 4 days, P=0.83). We observed no difference in all-cause mortality rate and readmission rate between the groups (P=0.75, P=0.97). CONCLUSION: Prolonged ICU hospitalizations in addition to use of invasive devices and antibiotics exposure correlate with a higher risk of developing MDR-GNB colonization and infection in COVID-19 critically ill patients. |
format | Online Article Text |
id | pubmed-8884770 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88847702022-03-01 Multidrug resistant Gram-negative bacilli infection in critically ill patients with Coronavirus disease 2019 Allende, N. García Álvarez, V. Quiroga, M.P. Massó, M. Centrón, D. Campos, J. Fox, B. Canigia, L.B. Fernandez Int J Infect Dis Ps07.14 (834) PURPOSE: Rapid spread of multidrug resistant Gram-negative bacilli (MDR-GNB) infection in Coronavirus disease (COVID-19) critically ill patients was observed even in those without underlying diseases and in all age groups. We conducted a prospective cohort study to assess the risk factors for acquisition of MDR-GNB infection in COVID-19 patients and its impact on patients´ outcome. METHODS & MATERIALS: We included 43 consecutive patients with COVID-19 from a total of 8874 patients with COVID-19 admitted into the ICU of Aleman Hospital, Argentina, from May 1st 2020 to June 30th 2021. Followed up until death or 30 days after hospital discharge. We divided them into 4 groups: colonized with MDR-GNB (G1), colonized with MDR-GNB and infected with non-carbapenem resistant bacteria (G2), colonized and infected with MDR-GNB (G3), and infected with MDR-GNB without previous colonization (G4). Microbiological sampling was performed according to patient's conditions or epidemiological surveillance. Outcomes considered were length of hospital stay (LOS), mortality and readmission rate. RESULTS: Seven, five, six and twenty five patients were distributed respectively in G1, G2, G3 and G4. Male/female ratio was 2:1 with a median age of 68 years (IQR 62–75). Chronic pulmonary disease (18.6%) was the main comorbidity. Mean LOS was 40.16 days (P=0.79). Prolonged biomedical devices used were observed in 93% of patients (P=0.33). Ventilator associated pneumonia (n:15/36) and catheter-related bloodstream infection (n:16/36) were the most frequent infections (P=0.29, P=0.69). The most common carbapenem-resistant pathogens were Klebsiella pneumoniae (n: 38/60) and Pseudomonas aeruginosa (n:8/60). All patients were exposed to antibiotics before MDR-GNB was diagnosed. The first isolation of MDR-GNB was on average 14 days after hospital admission (P=0,84). Time between MDR-GNB colonization and infection was twice as much between G2 and G3 (8.4 Vs. 4 days, P=0.83). We observed no difference in all-cause mortality rate and readmission rate between the groups (P=0.75, P=0.97). CONCLUSION: Prolonged ICU hospitalizations in addition to use of invasive devices and antibiotics exposure correlate with a higher risk of developing MDR-GNB colonization and infection in COVID-19 critically ill patients. Published by Elsevier Ltd. 2022-03 2022-02-28 /pmc/articles/PMC8884770/ http://dx.doi.org/10.1016/j.ijid.2021.12.130 Text en Copyright © 2021 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Ps07.14 (834) Allende, N. García Álvarez, V. Quiroga, M.P. Massó, M. Centrón, D. Campos, J. Fox, B. Canigia, L.B. Fernandez Multidrug resistant Gram-negative bacilli infection in critically ill patients with Coronavirus disease 2019 |
title | Multidrug resistant Gram-negative bacilli infection in critically ill patients with Coronavirus disease 2019 |
title_full | Multidrug resistant Gram-negative bacilli infection in critically ill patients with Coronavirus disease 2019 |
title_fullStr | Multidrug resistant Gram-negative bacilli infection in critically ill patients with Coronavirus disease 2019 |
title_full_unstemmed | Multidrug resistant Gram-negative bacilli infection in critically ill patients with Coronavirus disease 2019 |
title_short | Multidrug resistant Gram-negative bacilli infection in critically ill patients with Coronavirus disease 2019 |
title_sort | multidrug resistant gram-negative bacilli infection in critically ill patients with coronavirus disease 2019 |
topic | Ps07.14 (834) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884770/ http://dx.doi.org/10.1016/j.ijid.2021.12.130 |
work_keys_str_mv | AT allendengarcia multidrugresistantgramnegativebacilliinfectionincriticallyillpatientswithcoronavirusdisease2019 AT alvarezv multidrugresistantgramnegativebacilliinfectionincriticallyillpatientswithcoronavirusdisease2019 AT quirogamp multidrugresistantgramnegativebacilliinfectionincriticallyillpatientswithcoronavirusdisease2019 AT massom multidrugresistantgramnegativebacilliinfectionincriticallyillpatientswithcoronavirusdisease2019 AT centrond multidrugresistantgramnegativebacilliinfectionincriticallyillpatientswithcoronavirusdisease2019 AT camposj multidrugresistantgramnegativebacilliinfectionincriticallyillpatientswithcoronavirusdisease2019 AT foxb multidrugresistantgramnegativebacilliinfectionincriticallyillpatientswithcoronavirusdisease2019 AT canigialbfernandez multidrugresistantgramnegativebacilliinfectionincriticallyillpatientswithcoronavirusdisease2019 |